Abstract
Pharmacologically, a decrease in sinus heart rate can be achieved by several means: indirectly, via inhibition of the autonomic nervous system, and directly at the pacemaker cells of the atrial sinus node. The term “Specific Bradycardic Agents” has been proposed for drugs which directly decrease the sinus rate in doses or concentrations smaller than are necessary to elicit other pharmacological effects [1, 7, 9, 10, 13]. ULFS 49 CL is such a new, specific, negative chronotropic agent which directly decreases the spontaneous heart rate by slowing the diastolic depolarization of the pacemaker cells in the sinu-atrial node [6, 8, 11].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bouman LN, Ginneken A van, Opthof T, Duivenvoorden JJ (1986) Electrophysiology of sinoatrial node and the action of specific bradycardic agents (SBA), a novel approach to cardiac physiology and therapy. International workshop at the Ernst Boehringer Institut, Bender u. Co
Buckberg GD, Fixier DE, Archie JP, Hoffman JIE (1972) Experimental subendocardial ischemia in dogs with normal coronary arteries. Circ Res, 30: 67–81
Buckberg GD, Fixier DE, Archie JP, Henney RP, Hoffman JIE (1975) Variable effects of heart rate on phasic and regional left ventricular muscle blood flow in anesthetized dogs. Cardiovasc Res 9: 1–11
Connoly ME, Kersting F, Dollery CT (1976) The clinical pharmacology of beta-adrenergic blocking drugs. Prog Cardiovasc Dis 19: 203–49
Dämmgen JW, Lamping KA, Gross GJ (1985) Action of two new bradycardic agents, AQ-AH 208 and ULFS 49, on ischemic myocardial perfusion and function. J Cardiovasc Pharmacol 7: 71–79
Gruber R, Lumper G, Zilberszac A, Heistracher P (1983) Effects of ULFS 49 CL on the action potential of the guinea-pig heart. Naunyn-Schmiedeberg’s Arch. Pharmacol. 324, R 32
Heistracher P (1986) Specific bradycardic agents: Introduction; specific bradycardic agents, a novel approach to cardiac physiology and therapy. International workshop at the Ernst-Boehringer-Institut, Bender u. Co
Kobinger W, Lillie C (1984a) Cardiovascular characterization of ULFS 49 CL, a new “specific bradycardic agent”. Eur. J. Pharmacol. 104: 9–18
Kobinger W, Lillie C (1984b) New Drugs Annual: Cardiovascular Drugs, Vol. 2, Chapter 10, 193–210, ed. by Alexander Scriabine, Raven Press, New York
Kobinger W (1985) Specific bradycardic agents, a new approach to therapy in angina pectoris? Prog Pharmacol 5 (3), 89–100
Lillie C, Kobinger W (1983) Cardiovascular actions of ULFS 49, a new “specific bradycardic agent”, Naunyn-Schmiedeberg’s Arch. Pharmacol. 324, R 33
Mc Allister RG Jr. (1982) Clinical pharmacology of slow channel calcium blocking agents. Prog Cardiovasc Dis 25: 83–102
Reiffen M (1985) Specific bradycardic agents—a new principle in coronary heart disease 189th ACS National Meeting, American Chemical Society, Division of Medical Chemistry Abstr 41
Senges Rizos I, Brachmann J, Anders G, Jauerning R, Hamman H-D, Kübler W (1983) Effect of nifedipine and AQ-A39 on the sinoatrial and atrioventricular nodes of the rabbit and their antiarrhythmic action on atrioventricular nodal reentrant tachycardia. Cardiovasc Res 17: 132–144
Sonnenblick EH; Skeleton CL (1971) Oxygen consumption of the heart: Physiological principles and clinical implications. Mod concepts Cardiovasc Dis 40, 9–16
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt
About this paper
Cite this paper
Seidl, K., Hauer, B., Lengfelder, W., Senges, J. (1991). Electrophysiological effects of ULFS 49 CL. In: Hjalmarson, Å., Remme, W.J. (eds) Sinus node inhibitors. Steinkopff. https://doi.org/10.1007/978-3-642-72458-9_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-72458-9_4
Publisher Name: Steinkopff
Print ISBN: 978-3-7985-0861-3
Online ISBN: 978-3-642-72458-9
eBook Packages: Springer Book Archive